医学
血红蛋白
四分位间距
置信区间
随机对照试验
麻醉
外科
相对风险
前瞻性队列研究
内科学
作者
Sun-Kyung Park,Chahnmee Hur,Young‐Won Kim,Seung Hoon Yoo,Young-Jin Lim,Jin‐Tae Kim
标识
DOI:10.1016/j.jclinane.2023.111326
摘要
The effect of noninvasive CO-oximetry hemoglobin (SpHb) monitoring on the clinical outcomes of patients undergoing surgery remains unclear. This trial aimed to evaluate whether SpHb monitoring helps maintain hemoglobin levels within a predefined target range during major noncardiac surgeries with a potential risk of intraoperative hemorrhage.A single-center, prospective, randomized controlled trial.University hospital.One hundred and thirty patients undergoing elective noncardiac surgery with a potential risk of hemorrhage.Patients were randomly allocated to undergo either SpHb-guided management (SpHb group) or usual care (control group).The primary outcome was the rate of deviation of the total hemoglobin concentration (determined from laboratory testing) from a pre-specified target range (8-14 g/dL). This was defined as the number of laboratory tests revealing such deviations divided by the total number of laboratory tests performed during the surgery.The primary outcome occurred significantly less frequently in the SpHb group as compared to that in the control group (15/555 [2.7%]) vs. 68/598 [11.4%]; relative risk, 0.24; 95% confidence interval, 0.13-0.41; P < 0.001). Fewer point-of-care blood tests were performed in the SpHb group than in the control group (median [interquartile range], 2 [1-4] vs. 4 [2-5]; P < 0.001). There were no significant intergroup differences in the number of patients who received red blood cell transfusions during surgery (SpHb vs. control, 33.8% vs. 46.2%; P = 0.201). The incidence of unnecessary red blood cell preparation (>2 units) was lower in the SpHb group than in the control group (3.1% vs. 16.9%; P = 0.024).Compared with routine care, SpHb-guided management resulted in significantly lower rates of hemoglobin deviation outside the target range intraoperatively in patients undergoing major noncardiac surgeries with a potential risk of hemorrhage.ClinicalTrials.gov (identifier: NCT03816514).
科研通智能强力驱动
Strongly Powered by AbleSci AI